Abstract
A major challenge in the development of a successful tumor vaccination is to break immune tolerance and to sensitize efficiently the immune system toward relevant tumor antigens, thus enabling T-cell-mediated antitumor responses in vivo. Dendritic cell (DC)-based immunotherapy shows the advantage to induce an adaptive immune response against the tumor, with the potential to generate a long-lasting immunological memory able to prevent further relapses and hopefully metastasis. Recently different preclinical studies highlighted the golden opportunity to exploit the features of immunogenic cell death (ICD) to generate ex vivo a highly immunogenic tumor cell lysate as potent antigen formulation for improved DC-based vaccine against aggressive cancers. This chapter focuses on the methods to obtain tumor lysates from cells undergoing ICD to be used for DC pulsing and to test the functionality of the generated DCs for antitumor vaccine development.
| Language | English |
|---|---|
| Title of host publication | Methods in Molecular Biology |
| Publisher | Humana Press Inc. |
| Pages | 317-333 |
| Number of pages | 17 |
| DOIs | |
| Publication status | Published - Jan 1 2019 |
Publication series
| Name | Methods in Molecular Biology |
|---|---|
| Volume | 1884 |
| ISSN (Print) | 1064-3745 |
Keywords
- Active immunotherapy
- Anticancer vaccine
- Dendritic cells
- Immunogenic cell death
ASJC Scopus subject areas
- Molecular Biology
- Genetics
Cite this
A novel dendritic cell-based vaccination protocol to stimulate immunosurveillance of aggressive cancers. / Nigro, Annunziata; Montico, Barbara; Casolaro, Vincenzo; Dal Col, Jessica.
Methods in Molecular Biology. Humana Press Inc., 2019. p. 317-333 (Methods in Molecular Biology; Vol. 1884).Research output: Chapter in Book/Report/Conference proceeding › Chapter
}
TY - CHAP
T1 - A novel dendritic cell-based vaccination protocol to stimulate immunosurveillance of aggressive cancers
AU - Nigro, Annunziata
AU - Montico, Barbara
AU - Casolaro, Vincenzo
AU - Dal Col, Jessica
PY - 2019/1/1
Y1 - 2019/1/1
N2 - A major challenge in the development of a successful tumor vaccination is to break immune tolerance and to sensitize efficiently the immune system toward relevant tumor antigens, thus enabling T-cell-mediated antitumor responses in vivo. Dendritic cell (DC)-based immunotherapy shows the advantage to induce an adaptive immune response against the tumor, with the potential to generate a long-lasting immunological memory able to prevent further relapses and hopefully metastasis. Recently different preclinical studies highlighted the golden opportunity to exploit the features of immunogenic cell death (ICD) to generate ex vivo a highly immunogenic tumor cell lysate as potent antigen formulation for improved DC-based vaccine against aggressive cancers. This chapter focuses on the methods to obtain tumor lysates from cells undergoing ICD to be used for DC pulsing and to test the functionality of the generated DCs for antitumor vaccine development.
AB - A major challenge in the development of a successful tumor vaccination is to break immune tolerance and to sensitize efficiently the immune system toward relevant tumor antigens, thus enabling T-cell-mediated antitumor responses in vivo. Dendritic cell (DC)-based immunotherapy shows the advantage to induce an adaptive immune response against the tumor, with the potential to generate a long-lasting immunological memory able to prevent further relapses and hopefully metastasis. Recently different preclinical studies highlighted the golden opportunity to exploit the features of immunogenic cell death (ICD) to generate ex vivo a highly immunogenic tumor cell lysate as potent antigen formulation for improved DC-based vaccine against aggressive cancers. This chapter focuses on the methods to obtain tumor lysates from cells undergoing ICD to be used for DC pulsing and to test the functionality of the generated DCs for antitumor vaccine development.
KW - Active immunotherapy
KW - Anticancer vaccine
KW - Dendritic cells
KW - Immunogenic cell death
UR - http://www.scopus.com/inward/record.url?scp=85056920054&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85056920054&partnerID=8YFLogxK
U2 - 10.1007/978-1-4939-8885-3_22
DO - 10.1007/978-1-4939-8885-3_22
M3 - Chapter
T3 - Methods in Molecular Biology
SP - 317
EP - 333
BT - Methods in Molecular Biology
PB - Humana Press Inc.
ER -